MDMA Reimbursement Conference Notes: 2019

MDMA Reimbursement Conference Notes 2019 - Top Takeaways from sessions at the Medical Device Manufacturers Association Healthcare Policy and Reimbursement Conference

Perspectives on Medical Reimbursement By JR Associates The Medical Device Manufacturers Association’s annual Coverage, Reimbursement and Health Policy Conference is always a high point on our firm’s schedule. That’s because our President, Judy Rosenbloom, and our VP of Global Health Policy, Jo Ellen Slurzberg, work hand-in-hand with MDMA each year to develop and deliver this educational event. Our relationship with…

Read More »

Can Innovation Solve the Healthcare Economics Crisis? Panel Notes

Can medical technology innovation solve the healthcare economics crisis? Read summary notes from this MDG Boston panel discussion

Perspectives on Medical Reimbursement By JR Associates   Recently, our VP of Global Health Policy, Jo Ellen Slurzberg moderated a compelling roundtable discussion at MDG Boston, a leading member-based community for medical device and technology professionals. This session focused on one of the industry’s most formidable issues: U.S. Healthcare Economics – Innovating Our Way Out of a…

Read More »

MDMA Reimbursement Conference Notes: 2018

MDMA Reimbursement Conference Notes 2018

Perspectives on Medical Reimbursement By JR Associates Among our consultants, the MDMA Coverage, Reimbursement and Health Policy Conference is more than just another event on the business calendar. For us, it is an important professional tradition that began 21 years ago. That’s when our President, Judy Rosenbloom, and VP of Global Health Policy, Jo Ellen…

Read More »

MDMA Reimbursement Conference Notes 2017

MDMA Reimbursement Conference speakers provide highlights from their sessions at the 2017 forum

Perspectives on Medical Reimbursement By JR Associates Over the years, our consultants have developed strong, productive working relationships with many influential medical and biotech industry associations, including the Medical Device Manufacturers Association (MDMA). One of the highlights of MDMA’s annual events calendar is its Coverage, Reimbursement and Health Policy Conference, where our leaders have participated as featured…

Read More »

Medical Device Innovation and Reimbursement: MDMA 2016 Conference Notes

Read notes from MDMA Reimbursement Conference presentations 2016

Perspectives on Medical Reimbursement By JR Associates Through the years, our consultants have become popular as featured speakers at a variety of prestigious medical technology forums. But the highlight of our annual events calendar is always the MDMA Coverage, Reimbursement & Health Policy Conference. It is deeply rewarding to connect directly with medical device professionals and discuss critical…

Read More »

MDMA Reimbursement Conference Notes: 2015

Perspectives on Medical Reimbursement By JR Associates For years, our consultants have been featured speakers at the MDMA Annual Coverage, Reimbursement & Health Policy Conference — and the 2015 conference was no exception. Our Founder and President, Judy Rosenbloom, teamed with VP Health Policy, Jo Ellen Slurzberg, to share their expertise with the medical device manufacturing community in…

Read More »

Medical Device Coverage: Do Private Payers Follow Medicare’s Lead?

Perspectives on Medical Reimbursement By JR Associates When making decisions about medical device coverage, do private insurers take their cues from Medicare (CMS)? Not necessarily, according to a recent study published in the peer-review journal, Health Affairs. According to the research abstract, an analysis of CMS national coverage decisions (NCDs) revealed that: ~50% were equivalent to corresponding private payer policies ~25% were…

Read More »

Amyvid & Alzheimers Lesson: FDA Approval Is Not A Coverage Guarantee

Perspectives on Medical Reimbursement By JR Associates The path to advancements in disease detection and treatment is notoriously complex, circuitous and costly. However, even after FDA approval, there are no guarantees of reimbursement through CMS coverage. This is an essential lesson in the case of Eli Lilly’s Amyvid PET scan imaging agent, which is used…

Read More »